Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteMiransertib (ARQ-092) is a potent, selective and orally bioavailable allosteric inhibitor of Akt with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively.
More Information Supplier PageMirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
More Information Supplier PageMirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
More Information Supplier PageMirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
More Information Supplier PageMirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
More Information Supplier PageMirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
More Information Supplier PageMirikizumab (Anti-IL-23) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23. Mirikizumab can be used for research on ulcerative colitis. MW: 144.26 KD.
More Information Supplier PageMirikizumab (Anti-IL-23) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23. Mirikizumab can be used for research on ulcerative colitis. MW: 144.26 KD.
More Information Supplier PageMirikizumab (Anti-IL-23) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23. Mirikizumab can be used for research on ulcerative colitis. MW: 144.26 KD.
More Information Supplier PageMirin is a potent Mre11–Rad50–Nbs1 (MRN) complex inhibitor, and inhibits Mre11-associated exonuclease activity. Mirin inhibits MRN-dependent activation of ATM.
More Information Supplier PageMirin is a potent Mre11–Rad50–Nbs1 (MRN) complex inhibitor, and inhibits Mre11-associated exonuclease activity. Mirin inhibits MRN-dependent activation of ATM.
More Information Supplier PageMirin is a potent Mre11–Rad50–Nbs1 (MRN) complex inhibitor, and inhibits Mre11-associated exonuclease activity. Mirin inhibits MRN-dependent activation of ATM.
More Information Supplier PageMirin is a potent Mre11–Rad50–Nbs1 (MRN) complex inhibitor, and inhibits Mre11-associated exonuclease activity. Mirin inhibits MRN-dependent activation of ATM.
More Information Supplier PageMiriplatin (SM-11355) is a derivative of cisplatin containing myristates as a carrier ligand. It is a novel lipophilic platinum complex developed to treat hepatocellular carcinoma.DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.
More Information Supplier PageMiriplatin (SM-11355) is a derivative of cisplatin containing myristates as a carrier ligand. It is a novel lipophilic platinum complex developed to treat hepatocellular carcinoma.DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.
More Information Supplier PageMirodenafil Dihydrochloride(SK-3530 dihydrochloride) is an oral phosphodiesterase type 5 (PDE-5) inhibitor used to treat erectile dysfunction (ED).
More Information Supplier PageMirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand that has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain.
More Information Supplier PageMirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand that has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain.
More Information Supplier PageMirtazapine (Org3770,6-Azamianserin) is an adrenergic and seroton receptor antagonist, used to treat depression.
More Information Supplier PageMirtazapine (Org3770,6-Azamianserin) is an adrenergic and seroton receptor antagonist, used to treat depression.
More Information Supplier PageMirvetuximab (Anti-FOLR1) is a monoclonal antibody targeting FOLR1 (folate receptor 1). Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). MW: 145.2 KD
More Information Supplier PageMirvetuximab (Anti-FOLR1) is a monoclonal antibody targeting FOLR1 (folate receptor 1). Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). MW: 145.2 KD
More Information Supplier PageMirvetuximab (Anti-FOLR1) is a monoclonal antibody targeting FOLR1 (folate receptor 1). Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). MW: 145.2 KD
More Information Supplier PageMirvetuximab-MMAE is an ADC targeting FOLR1 (folate receptor 1). It can be used in ovarian and other FRα-positive cancer research. MW :145.96 KD.
More Information Supplier PageMirvetuximab-MMAE is an ADC targeting FOLR1 (folate receptor 1). It can be used in ovarian and other FRα-positive cancer research. MW :145.96 KD.
More Information Supplier PageMirvetuximab-MMAE is an ADC targeting FOLR1 (folate receptor 1). It can be used in ovarian and other FRα-positive cancer research. MW :145.96 KD.
More Information Supplier PageMirzotamab (Anti-B7-H3 / CD276) is a human IgG1κ monoclonal antibody targeting CD276/B7-H3. Mirzotamab is used to produce Mirzotamab clezutoclax antibody drug conjugate (ADC). MW: 144.86 KD.
More Information Supplier PageMirzotamab (Anti-B7-H3 / CD276) is a human IgG1κ monoclonal antibody targeting CD276/B7-H3. Mirzotamab is used to produce Mirzotamab clezutoclax antibody drug conjugate (ADC). MW: 144.86 KD.
More Information Supplier PageMirzotamab (Anti-B7-H3 / CD276) is a human IgG1κ monoclonal antibody targeting CD276/B7-H3. Mirzotamab is used to produce Mirzotamab clezutoclax antibody drug conjugate (ADC). MW: 144.86 KD.
More Information Supplier PageMisoprostol(SC29333) is a synthetic prostaglandin E1 (PGE1) analog that is used to prevent gastric ulcers, to treat missed miscarriage, to induce labor, and to induce abortion.
More Information Supplier PageMitapivat (AG-348) is an activator of a pyruvate kinase PKM2, an enzyme involved in glycolysis.
More Information Supplier PageMitapivat (AG-348) is an activator of a pyruvate kinase PKM2, an enzyme involved in glycolysis.
More Information Supplier PageMitapivat (AG-348) is an activator of a pyruvate kinase PKM2, an enzyme involved in glycolysis.
More Information Supplier PageMitapivat (AG-348) is an activator of a pyruvate kinase PKM2, an enzyme involved in glycolysis.
More Information Supplier PageMitapivat (AG-348) is an activator of a pyruvate kinase PKM2, an enzyme involved in glycolysis.
More Information Supplier PageMitazalimab (Anti-TNFRSF5 / CD40) a human agonist IgG1 antibody targeting CD40. It enhances the anti-tumor efficacy of a model cancer vaccine. MW :143.44 KD.
More Information Supplier PageMitazalimab (Anti-TNFRSF5 / CD40) a human agonist IgG1 antibody targeting CD40. It enhances the anti-tumor efficacy of a model cancer vaccine. MW :143.44 KD.
More Information Supplier PageMitazalimab (Anti-TNFRSF5 / CD40) a human agonist IgG1 antibody targeting CD40. It enhances the anti-tumor efficacy of a model cancer vaccine. MW :143.44 KD.
More Information Supplier PageMitiglinide Calcium (KAD-1229) is a blood glucose-lowering drugs, stimulating insulin secretion by closing the ATP-sensitive K+ channels in pancreatic beta-cells.
More Information Supplier PageMiTMAB is a selective dynamin inhibitor that targets the dynamin-phospholipid interaction. MiTMAB inhibits dynamin GTPase activity with a Ki of 940 nM.
More Information Supplier PageMito-TEMPO (MT), a mitochondria-targeted superoxide dismutase mimetic, protects against the early phase of acetaminophen (APAP) hepatotoxicity by inhibiting peroxynitrite formation. Mito-TEMPO treatment inhibits APAP-induced RIP3 kinase expression.
More Information Supplier PageMito-TEMPO (MT), a mitochondria-targeted superoxide dismutase mimetic, protects against the early phase of acetaminophen (APAP) hepatotoxicity by inhibiting peroxynitrite formation. Mito-TEMPO treatment inhibits APAP-induced RIP3 kinase expression.
More Information Supplier PageMito-TEMPO (MT), a mitochondria-targeted superoxide dismutase mimetic, protects against the early phase of acetaminophen (APAP) hepatotoxicity by inhibiting peroxynitrite formation. Mito-TEMPO treatment inhibits APAP-induced RIP3 kinase expression.
More Information Supplier PageMito-TEMPO (MT), a mitochondria-targeted superoxide dismutase mimetic, protects against the early phase of acetaminophen (APAP) hepatotoxicity by inhibiting peroxynitrite formation. Mito-TEMPO treatment inhibits APAP-induced RIP3 kinase expression.
More Information Supplier PageMito-TEMPO (MT), a mitochondria-targeted superoxide dismutase mimetic, protects against the early phase of acetaminophen (APAP) hepatotoxicity by inhibiting peroxynitrite formation. Mito-TEMPO treatment inhibits APAP-induced RIP3 kinase expression.
More Information Supplier PageA unique collection of 719 compounds targeting mitochondria, used for high-throughput screening (HTS) and high-content screening (HCS).
More Information Supplier PageMitochondrial fusion promoter M1 is a mitochondrial dynamic modulator that increases the expression of mitofusin 2, a mitochondrial outer membrane fusion protein, reduces brain mitochondrial dysfunction. Mitochondrial fusion promoter M1 alleviates brain damage in rats with cardiac ischemia/reperfusion injury.
More Information Supplier PageMitochondrial fusion promoter M1 is a mitochondrial dynamic modulator that increases the expression of mitofusin 2, a mitochondrial outer membrane fusion protein, reduces brain mitochondrial dysfunction. Mitochondrial fusion promoter M1 alleviates brain damage in rats with cardiac ischemia/reperfusion injury.
More Information Supplier PageMitochonic acid 5 (MA-5) reduces mitochondrial apoptosis via upregulation of mitophagy. Mitochonic acid 5 regulates mitophagy via Bnip3 through the MAPK-ERK-Yap signaling pathway. Mitochonic acid 5 modulates mitochondrial ATP synthesis.
More Information Supplier PageMitochonic acid 5 (MA-5) reduces mitochondrial apoptosis via upregulation of mitophagy. Mitochonic acid 5 regulates mitophagy via Bnip3 through the MAPK-ERK-Yap signaling pathway. Mitochonic acid 5 modulates mitochondrial ATP synthesis.
More Information Supplier Page
